Journal of Holistic Integrative Pharmacy最新文献_第6页

Visual analysis of drug research and development based on artificial intelligence 基于人工智能的药物研发可视化分析

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.12.002

Wei Wei , Chao Song , Changxing Qi , Xin Zhang , Xiaoyi Zhang , Run Pu , Yi Ao

The iteration of artificial intelligence (AI) technology provides new opportunities for drug research and experimental development. In recent years, AI-based drug research has continuously made new progress and has garnered widespread attention. This study retrieved data from a total of 23,096 papers in AI-based drug research and development from the Web of Science up to May 14, 2024, and conducted bibliometric analysis using VOSviewer software. The results indicated that the AI-based drug research and development is a globally recognized hotspot, and the United States holds a certain authority in this field, while China ranks second in total publication output. The integration of AI technology with drug development primarily involves four stages: drug discovery, preclinical research, clinical trials, and drug manufacturing. So, AI technology has been applied throughout the entire process of drug development. AI-based virtual drug screening and structure-activity relationship analysis started early, while graph neural networks, pre-trained models (Transformer), interpretable AI technology, ChatGPT, and large language models were significantly highlighted in the last 3 years. Moreover, since 2020, AI-based drug repurposing, molecular dynamics simulation, 3D printing, and drug delivery system design have emerged as research hotspots and have been mainly applied to, particularly, on COVID-19, disease prognosis, liver cancer, lung cancer, and immunotherapy.

人工智能（AI）技术的迭代为药物研究和实验开发提供了新的机遇。近年来，基于人工智能的药物研究不断取得新进展，受到广泛关注。本研究从Web of Science截至2024年5月14日的23,096篇基于人工智能的药物研发论文中检索数据，使用VOSviewer软件进行文献计量学分析。结果表明，基于人工智能的药物研发是全球公认的热点，美国在该领域拥有一定的权威，而中国在该领域的总发表量排名第二。人工智能技术与药物开发的整合主要涉及四个阶段：药物发现、临床前研究、临床试验和药物生产。因此，人工智能技术已经应用于药物开发的整个过程。基于人工智能的虚拟药物筛选和构效关系分析起步较早，而图神经网络、预训练模型（Transformer）、可解释性人工智能技术、ChatGPT和大型语言模型在最近3年得到了显著的突出。此外，自2020年以来，基于人工智能的药物再利用、分子动力学模拟、3D打印、给药系统设计等成为研究热点，主要应用于COVID-19、疾病预后、肝癌、肺癌、免疫治疗等领域。

{"title":"Visual analysis of drug research and development based on artificial intelligence","authors":"Wei Wei , Chao Song , Changxing Qi , Xin Zhang , Xiaoyi Zhang , Run Pu , Yi Ao","doi":"10.1016/j.jhip.2024.12.002","DOIUrl":"10.1016/j.jhip.2024.12.002","url":null,"abstract":"<div><div>The iteration of artificial intelligence (AI) technology provides new opportunities for drug research and experimental development. In recent years, AI-based drug research has continuously made new progress and has garnered widespread attention. This study retrieved data from a total of 23,096 papers in AI-based drug research and development from the Web of Science up to May 14, 2024, and conducted bibliometric analysis using VOSviewer software. The results indicated that the AI-based drug research and development is a globally recognized hotspot, and the United States holds a certain authority in this field, while China ranks second in total publication output. The integration of AI technology with drug development primarily involves four stages: drug discovery, preclinical research, clinical trials, and drug manufacturing. So, AI technology has been applied throughout the entire process of drug development. AI-based virtual drug screening and structure-activity relationship analysis started early, while graph neural networks, pre-trained models (Transformer), interpretable AI technology, ChatGPT, and large language models were significantly highlighted in the last 3 years. Moreover, since 2020, AI-based drug repurposing, molecular dynamics simulation, 3D printing, and drug delivery system design have emerged as research hotspots and have been mainly applied to, particularly, on COVID-19, disease prognosis, liver cancer, lung cancer, and immunotherapy.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 323-332"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study on the application of Aloe vera in cosmetology and clinical treatment of skin diseases 芦荟在美容及皮肤病临床治疗中的应用研究

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.006

Jiajun Zhu , Yuanru Zheng , Yanhui Ge

The medicinal value of Aloe vera (AV) has been continuously explored and utilized in recent years, becoming a research hotspot. Some basic studies have found that AV had cosmetic effects such as whitening, sun protection, antioxidant, anti-aging, and moisturizing. Some clinical trials have found that AV had medical effects such as antibacterial, anti-damage, and promoting wound healing. In this work, we summarized the indications and therapeutic efficacy of AV in cosmetology and clinical treatment of dermatosis, in order to provide certain inspiration for the development of new AV-based skincare products and new medicines for skin diseases.

近年来，芦荟（AV）的药用价值不断被发掘和利用，成为研究热点。一些基础研究发现，AV具有美白、防晒、抗氧化、抗衰老、保湿等美容功效。一些临床试验发现，AV具有抗菌、抗损伤、促进伤口愈合等医学作用。本文综述了AV在美容和皮肤病临床治疗中的适应症和疗效，以期为开发基于AV的新型护肤品和皮肤病新药提供一定的启示。

引用次数: 0

Human Epididymis Protein 4 (HE4) as a promising biomarker and therapy target in fibrotic diseases: A review 人附睾蛋白4 （HE4）作为纤维化疾病的生物标志物和治疗靶点的研究进展

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.12.001

Huiqun Tian, Li Chen

The treatment of fibrosis faces a significant challenge due to the lack of effective therapies that can reverse established fibrosis. Early detection is vital for intervention, yet distinguishing fibrosis from normal tissue repair is complex. Human Epididymis Protein 4 (HE4), a traditional tumor marker, has been found to be increased in some non-neoplastic conditions, such as fibrosis related diseases. According to properties analysis, HE4 has been characterized as a highly stable cross-class protease inhibitor, which interacts with key fibrotic proteins (such as MMP2 and PRSS family members) and potentially involves in the progression of fibrosis by inhibiting the enzymatic activity of these proteins. Meanwhile, studies indicated that HE4 may be involved in fibrosis through PI3K/AKT, NF-κB, MAPK, and other signaling pathways. Here we summarized the latest research progress of HE4 in pulmonary fibrosis, renal fibrosis, myocardial fibrosis, liver fibrosis, and autoimmune diseases induced fibrosis. As reported in this review, HE4 was closely related to disease severity and prognosis, and also was a promising prognostic evaluation marker and therapeutic intervention target for fibrotic diseases.

由于缺乏能够逆转已形成的纤维化的有效疗法，纤维化的治疗面临着重大挑战。早期发现对干预至关重要，但区分纤维化和正常组织修复是很复杂的。人类附睾蛋白4 （HE4）是一种传统的肿瘤标志物，在一些非肿瘤性疾病，如纤维化相关疾病中被发现升高。根据性质分析，HE4是一种高度稳定的跨类蛋白酶抑制剂，可与关键纤维化蛋白（如MMP2和PRSS家族成员）相互作用，并可能通过抑制这些蛋白的酶活性参与纤维化的进展。同时，研究表明HE4可能通过PI3K/AKT、NF-κB、MAPK等信号通路参与纤维化。本文综述了HE4在肺纤维化、肾纤维化、心肌纤维化、肝纤维化及自身免疫性疾病纤维化中的最新研究进展。HE4与疾病严重程度和预后密切相关，是纤维化疾病预后评价指标和治疗干预靶点。

{"title":"Human Epididymis Protein 4 (HE4) as a promising biomarker and therapy target in fibrotic diseases: A review","authors":"Huiqun Tian, Li Chen","doi":"10.1016/j.jhip.2024.12.001","DOIUrl":"10.1016/j.jhip.2024.12.001","url":null,"abstract":"<div><div>The treatment of fibrosis faces a significant challenge due to the lack of effective therapies that can reverse established fibrosis. Early detection is vital for intervention, yet distinguishing fibrosis from normal tissue repair is complex. Human Epididymis Protein 4 (HE4), a traditional tumor marker, has been found to be increased in some non-neoplastic conditions, such as fibrosis related diseases. According to properties analysis, HE4 has been characterized as a highly stable cross-class protease inhibitor, which interacts with key fibrotic proteins (such as MMP2 and PRSS family members) and potentially involves in the progression of fibrosis by inhibiting the enzymatic activity of these proteins. Meanwhile, studies indicated that HE4 may be involved in fibrosis through PI3K/AKT, NF-κB, MAPK, and other signaling pathways. Here we summarized the latest research progress of HE4 in pulmonary fibrosis, renal fibrosis, myocardial fibrosis, liver fibrosis, and autoimmune diseases induced fibrosis. As reported in this review, HE4 was closely related to disease severity and prognosis, and also was a promising prognostic evaluation marker and therapeutic intervention target for fibrotic diseases.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 291-298"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research on the role and mechanism of Aloe vera (L.) Burm.f. in the treatment of burn: Based on network pharmacology analysis and experimental verification 芦荟的作用与机制研究Burm.f。在烧伤治疗中的应用：基于网络药理学分析和实验验证

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.001

Yixiang Wu , Xiaoshan Zheng , Youchaou Mobet , Huiqun Tian , Fangsen Li , Huan Li , Lifeng Xie , Yanyue Deng , Xiaodi Zhu , Chuxi Tang , Hongwei Shao , Song Liu

Burn is a suddenly occurring injury. The healing process of burn is complex. Aloe vera (L.) Burm.f. (Av) is widely used as Chinese folk medicine for the treatment of burn. While effective pharmacological components, role and mechanism of Av in the treatment of burn remain to be fully elucidated. Arachidonic Acid (AA) and Quercetin (QUE) are identified as active components of Av for the treatment of burn by network pharmacology analysis and experimental verification. Animal experiments’ results showed that AA and QUE could shorten the burn wound healing time. The expression of inflammatory factor TNF-α, MyD88 and P-NF-κB p65 were down-regulated and the ER (ESR1), SRC were up-regulated in AA treated NIH 3T3 cells. The expression of MyD88 was downregulated in QUE treated NIH 3T3 cells. The Av promotes burn healing may be via the anti-inflammatory effect and regulation on NF-κB signal pathway or estrogen signal pathway by its active components AA and QUE. This research may construct a bridge between Av and burn wounds, and skin therapy agent exploration.

烧伤是一种突然发生的伤害。烧伤的愈合过程是复杂的。芦荟（L.）Burm.f。被广泛用作治疗烧伤的民间药物。而Av在烧伤治疗中的有效药理成分、作用和机制尚不清楚。通过网络药理学分析和实验验证，确定花生四烯酸（AA）和槲皮素（QUE）是Av治疗烧伤的有效成分。动物实验结果表明，AA和QUE可缩短烧伤创面愈合时间。AA处理的NIH 3T3细胞炎症因子TNF-α、MyD88、P-NF-κB p65表达下调，ER （ESR1）、SRC表达上调。在QUE处理的NIH 3T3细胞中，MyD88的表达下调。Av促进烧伤愈合可能是通过其活性成分AA和QUE对NF-κB信号通路或雌激素信号通路的抗炎作用和调控作用。本研究可为Av与烧伤创面、皮肤治疗药物的探索搭建桥梁。

{"title":"Research on the role and mechanism of Aloe vera (L.) Burm.f. in the treatment of burn: Based on network pharmacology analysis and experimental verification","authors":"Yixiang Wu , Xiaoshan Zheng , Youchaou Mobet , Huiqun Tian , Fangsen Li , Huan Li , Lifeng Xie , Yanyue Deng , Xiaodi Zhu , Chuxi Tang , Hongwei Shao , Song Liu","doi":"10.1016/j.jhip.2024.11.001","DOIUrl":"10.1016/j.jhip.2024.11.001","url":null,"abstract":"<div><div>Burn is a suddenly occurring injury. The healing process of burn is complex. <em>Aloe vera</em> (L.) Burm.f. (Av) is widely used as Chinese folk medicine for the treatment of burn. While effective pharmacological components, role and mechanism of Av in the treatment of burn remain to be fully elucidated. Arachidonic Acid (AA) and Quercetin (QUE) are identified as active components of Av for the treatment of burn by network pharmacology analysis and experimental verification. Animal experiments’ results showed that AA and QUE could shorten the burn wound healing time. The expression of inflammatory factor TNF-α, MyD88 and P-NF-κB p65 were down-regulated and the ER (ESR1), SRC were up-regulated in AA treated NIH 3T3 cells. The expression of MyD88 was downregulated in QUE treated NIH 3T3 cells. The Av promotes burn healing may be via the anti-inflammatory effect and regulation on NF-κB signal pathway or estrogen signal pathway by its active components AA and QUE. This research may construct a bridge between Av and burn wounds, and skin therapy agent exploration.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 262-276"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pedalitin could regulate lipid metabolism and attenuate inﬂammatory factors in a non-alcoholic fatty liver disease cell model 在非酒精性脂肪肝细胞模型中，脚踏板可调节脂质代谢并减轻炎症因子

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.003

Wanying He , Yaying Yu , Hui He , Qian Huang , Zhiting Liu , Fan Yang , Lin Zhou

Nonalcoholic fatty liver disease (NAFLD) is an escalating global health issue, leading to liver fat accumulation, inflammation, fibrosis, and potential liver failure. In our preliminary network pharmacological study, it was hypothesized that Pedalitin (PED), a flavonoid found in black sesame plants, might exhibit protective effects against NAFLD. However, the effects and mechanisms of PED underlying its action on NAFLD are not yet fully understood. This study aimed to explore the potential effects and mechanisms of PED on NAFLD using a combination of network pharmacology, molecular docking, and the LO2 cell model. Potential targets for PED and NAFLD were predicted through public databases. Protein-protein interaction (PPI) networks were constructed, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Molecular docking was used to predict the target genes that could bind to PED. In vitro experiments using the LO2 cell model indicated that PED significantly reduced TG level (p < 0.05) and the formation of lipid droplets. The expression levels of key factors in fatty acid metabolism (CPT2, HADH), inflammatory factors (IL-17, TNF-α), and the FOXO signaling pathway (EGFR, IRS1, AKT1, FOXO1) were significantly downregulated in LO2 cells treated with PED (p < 0.05). In conclusion, PED may modulate local lipid metabolism and mitigate inflammatory responses through the FOXO signaling pathway.

非酒精性脂肪性肝病（NAFLD）是一个不断升级的全球健康问题，可导致肝脏脂肪堆积、炎症、纤维化和潜在的肝衰竭。在我们初步的网络药理学研究中，我们假设在黑芝麻植物中发现的黄酮类化合物Pedalitin （PED）可能对NAFLD具有保护作用。然而，PED对NAFLD作用的影响和机制尚不完全清楚。本研究旨在通过网络药理学、分子对接和LO2细胞模型相结合的方法，探讨PED对NAFLD的潜在作用及其机制。通过公共数据库预测PED和NAFLD的潜在靶点。构建蛋白-蛋白相互作用（PPI）网络，并进行基因本体（GO）和京都基因与基因组百科全书（KEGG）分析。利用分子对接技术预测可能与PED结合的靶基因。体外LO2细胞模型实验表明，PED显著降低TG水平(p <；0.05)和脂滴的形成。在PED处理的LO2细胞中，脂肪酸代谢关键因子（CPT2、HADH）、炎症因子（IL-17、TNF-α）和FOXO信号通路（EGFR、IRS1、AKT1、FOXO1）的表达水平显著下调(p <；0.05)。综上所述，PED可能通过FOXO信号通路调节局部脂质代谢，减轻炎症反应。

{"title":"Pedalitin could regulate lipid metabolism and attenuate inﬂammatory factors in a non-alcoholic fatty liver disease cell model","authors":"Wanying He , Yaying Yu , Hui He , Qian Huang , Zhiting Liu , Fan Yang , Lin Zhou","doi":"10.1016/j.jhip.2024.11.003","DOIUrl":"10.1016/j.jhip.2024.11.003","url":null,"abstract":"<div><div>Nonalcoholic fatty liver disease (NAFLD) is an escalating global health issue, leading to liver fat accumulation, inflammation, fibrosis, and potential liver failure. In our preliminary network pharmacological study, it was hypothesized that Pedalitin (PED), a flavonoid found in black sesame plants, might exhibit protective effects against NAFLD. However, the effects and mechanisms of PED underlying its action on NAFLD are not yet fully understood. This study aimed to explore the potential effects and mechanisms of PED on NAFLD using a combination of network pharmacology, molecular docking, and the LO2 cell model. Potential targets for PED and NAFLD were predicted through public databases. Protein-protein interaction (PPI) networks were constructed, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Molecular docking was used to predict the target genes that could bind to PED. <em>In vitro</em> experiments using the LO2 cell model indicated that PED significantly reduced TG level (<em>p</em> < 0.05) and the formation of lipid droplets. The expression levels of key factors in fatty acid metabolism (CPT2, HADH), inflammatory factors (IL-17, TNF-α), and the FOXO signaling pathway (EGFR, IRS1, AKT1, FOXO1) were significantly downregulated in LO2 cells treated with PED (<em>p</em> < 0.05). In conclusion, PED may modulate local lipid metabolism and mitigate inflammatory responses through the FOXO signaling pathway.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 314-322"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enlightenment of EU Herbal Medicinal Products regulation on the registration of Traditional Chinese Medicines in the Guangdong-Hong Kong-Macao Greater Bay Area 欧盟草药产品法规对粤港澳大湾区中药注册的启示

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.005

Ran Xiong , Hui Zhang , Yueyun Li , Guihao Zeng , Yonghui Liu , Yeyou Xu

Objective

This study analyzes the European Union's (EU's) regulatory practices of Herbal Medicinal Products (HMPs), aiming to provide implications for Traditional Chinese Medicines (TCMs) registration process within the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).

Methods

This paper conducts a comparative analysis of the regulatory agencies, legal frameworks, registration classifications, market authorization procedures, and the number of applications and approvals for both HMPs in the EU and TCMs in the GBA, thereby identifying the distinctive regulatory features across these regions.

Results

Our study finds that the EU has established a scientific, efficient, and harmonized regulation system for HMPs, whereas the registration of TCMs in the GBA is characterized by complexity and jurisdictional disparities in requirements and procedures. Drawing on the EU's advanced regulatory practices, the study offers recommendations to enhance the mutual recognition and accessibility of TCMs within the GBA.

Conclusion

This study offers a comprehensive understanding of the EU's HMPs regulation and the GBA's TCMs registration, contributing to the synergistic development of TCMs in the GBA.

目的分析欧盟（EU）草药产品（hmp）的监管实践，旨在为粤港澳大湾区（GBA）内的中药（tcm）注册流程提供启示。方法对欧盟和大湾区中药的监管机构、法律框架、注册分类、市场授权程序、申请和批准数量进行了比较分析，从而确定了这些地区不同的监管特征。结果欧盟已建立了科学、高效、统一的hmp监管体系，而大湾区中药注册在要求和程序上存在复杂性和管辖权差异。根据欧盟先进的监管实践，该研究提出了加强大湾区内中药相互认可和可及性的建议。结论本研究提供了对欧盟hmp法规和大湾区中药注册的全面了解，有助于大湾区中药的协同发展。

{"title":"Enlightenment of EU Herbal Medicinal Products regulation on the registration of Traditional Chinese Medicines in the Guangdong-Hong Kong-Macao Greater Bay Area","authors":"Ran Xiong , Hui Zhang , Yueyun Li , Guihao Zeng , Yonghui Liu , Yeyou Xu","doi":"10.1016/j.jhip.2024.11.005","DOIUrl":"10.1016/j.jhip.2024.11.005","url":null,"abstract":"<div><h3>Objective</h3><div>This study analyzes the European Union's (EU's) regulatory practices of Herbal Medicinal Products (HMPs), aiming to provide implications for Traditional Chinese Medicines (TCMs) registration process within the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).</div></div><div><h3>Methods</h3><div>This paper conducts a comparative analysis of the regulatory agencies, legal frameworks, registration classifications, market authorization procedures, and the number of applications and approvals for both HMPs in the EU and TCMs in the GBA, thereby identifying the distinctive regulatory features across these regions.</div></div><div><h3>Results</h3><div>Our study finds that the EU has established a scientific, efficient, and harmonized regulation system for HMPs, whereas the registration of TCMs in the GBA is characterized by complexity and jurisdictional disparities in requirements and procedures. Drawing on the EU's advanced regulatory practices, the study offers recommendations to enhance the mutual recognition and accessibility of TCMs within the GBA.</div></div><div><h3>Conclusion</h3><div>This study offers a comprehensive understanding of the EU's HMPs regulation and the GBA's TCMs registration, contributing to the synergistic development of TCMs in the GBA.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 344-353"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the mechanism of Lingbao Huxin Dan in the treatment of bradycardia based on atrioventricular node electrical signal conduction 基于房室结电信号传导探讨灵宝护心丹治疗心动过缓的作用机制

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.12.003

Jing Zhang , Guobin Zheng , Shangjing Liu , Yaodong Miao , Shu Yang , Sheng Li , Zhihui Yang , Danping Zhuo , Rui Guo , Yang Guo , Rongjiang Shao , Yunqing Hua , Chuanrui Ma

Background

Prolonged bradycardia leads to inadequate pumping of the heart, causing myocardial ischemia, which in turn affects cardiac function. Depending on its clinical features, improving the AV node conduction block may be an important tool to inhibit the progression of the disease. Lingbao Huxin Dan, which consists of several traditional Chinese medicines, is used for conditions similar to bradycardia and may be a potential therapeutic agent for bradycardia. In this experiment, we investigated its therapeutic significance and possible therapeutic targets for sinus bradycardia.

Methods

The bradycardia model of SD rats was prepared by using acetylcholine, propranolol, and verapamil respectively, and treated with Lingbao Huxin Dan for 3 weeks. At the end of treatment, the rats' ECG was recorded using a PV-LOOP heart rate recorder. The hearts and serum samples were collected to detect heart rate and related gene expression which were screened through network pharmacology analysis, as well as to evaluate the effect of Lingbao Huxin Dan on ion channels in the cardiac conduction system.

Results

Lingbao Huxin Dan improved the heart rate in the bradycardia model of SD rats and inhibited AV node conduction block by targeting ion channel proteins in the cardiac conduction system. The underlying molecular mechanism may be the activation of the β-adrenergic receptor-dependent cAMP/PKA signaling pathway targeted to enhance the expression of the pacing channel HCN4. In addition, Lingbao Huxin Dan prevented the deterioration of bradycardia by promoting the production of the oxygen radical scavenger SOD and inhibiting the upregulation of LDH due to cardiomyocyte damage.

Conclusions

Our study proved that Lingbao Huxin Dan alleviated bradycardia by downregulating CX45 and enhancing the expression of HCN4, ADRβ1, and TRPM7 to shorten the atrioventricular node induction period and improve sinoatrial node signaling. In addition, Lingbao Huxin Dan relieved myocardial injury induced by bradycardia by reducing the level of oxygen free radicals in the cardiac microenvironment.

背景：长期的心动过缓导致心脏供血不足，引起心肌缺血，进而影响心功能。根据其临床特点，改善房室结传导阻滞可能是抑制疾病进展的重要工具。灵宝护心丹由几种中药组成，用于治疗类似心动过缓的病症，可能是治疗心动过缓的潜在药物。本实验探讨其治疗窦性心动过缓的意义及可能的治疗靶点。方法分别用乙酰胆碱、心得安、维拉帕米制备SD大鼠心动过缓模型，并用灵宝护心丹治疗3周。在治疗结束时，使用PV-LOOP心率记录仪记录大鼠的心电图。采集心脏及血清样本，通过网络药理学分析筛选心率及相关基因表达，评价灵宝护心丹对心脏传导系统离子通道的影响。结果灵宝护心丹可提高SD大鼠心动过缓模型的心率，并通过靶向心脏传导系统的离子通道蛋白抑制房室结传导阻滞。其潜在的分子机制可能是激活β-肾上腺素能受体依赖的cAMP/PKA信号通路，以增强起搏通道HCN4的表达。此外，灵宝护心丹通过促进氧自由基清除剂SOD的产生，抑制心肌细胞损伤引起的LDH上调，从而防止心动过缓的恶化。结论灵宝护心丹通过下调CX45，提高HCN4、ADRβ1、TRPM7的表达，缩短房室结诱导期，改善窦房结信号传导，减轻心动过缓。此外，灵宝护心丹可通过降低心脏微环境中氧自由基水平减轻心动过缓所致心肌损伤。

{"title":"Exploring the mechanism of Lingbao Huxin Dan in the treatment of bradycardia based on atrioventricular node electrical signal conduction","authors":"Jing Zhang , Guobin Zheng , Shangjing Liu , Yaodong Miao , Shu Yang , Sheng Li , Zhihui Yang , Danping Zhuo , Rui Guo , Yang Guo , Rongjiang Shao , Yunqing Hua , Chuanrui Ma","doi":"10.1016/j.jhip.2024.12.003","DOIUrl":"10.1016/j.jhip.2024.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Prolonged bradycardia leads to inadequate pumping of the heart, causing myocardial ischemia, which in turn affects cardiac function. Depending on its clinical features, improving the AV node conduction block may be an important tool to inhibit the progression of the disease. Lingbao Huxin Dan, which consists of several traditional Chinese medicines, is used for conditions similar to bradycardia and may be a potential therapeutic agent for bradycardia. In this experiment, we investigated its therapeutic significance and possible therapeutic targets for sinus bradycardia.</div></div><div><h3>Methods</h3><div>The bradycardia model of SD rats was prepared by using acetylcholine, propranolol, and verapamil respectively, and treated with Lingbao Huxin Dan for 3 weeks. At the end of treatment, the rats' ECG was recorded using a PV-LOOP heart rate recorder. The hearts and serum samples were collected to detect heart rate and related gene expression which were screened through network pharmacology analysis, as well as to evaluate the effect of Lingbao Huxin Dan on ion channels in the cardiac conduction system.</div></div><div><h3>Results</h3><div>Lingbao Huxin Dan improved the heart rate in the bradycardia model of SD rats and inhibited AV node conduction block by targeting ion channel proteins in the cardiac conduction system. The underlying molecular mechanism may be the activation of the β-adrenergic receptor-dependent cAMP/PKA signaling pathway targeted to enhance the expression of the pacing channel HCN4. In addition, Lingbao Huxin Dan prevented the deterioration of bradycardia by promoting the production of the oxygen radical scavenger SOD and inhibiting the upregulation of LDH due to cardiomyocyte damage.</div></div><div><h3>Conclusions</h3><div>Our study proved that Lingbao Huxin Dan alleviated bradycardia by downregulating CX45 and enhancing the expression of HCN4, ADRβ1, and TRPM7 to shorten the atrioventricular node induction period and improve sinoatrial node signaling. In addition, Lingbao Huxin Dan relieved myocardial injury induced by bradycardia by reducing the level of oxygen free radicals in the cardiac microenvironment.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 333-343"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Network pharmacology-based study on the mechanism of Yiwei Decoction in chronic atrophic gastritis and experimental assessment 基于网络药理学的益胃汤治疗慢性萎缩性胃炎作用机制研究及实验评价

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-12-01 DOI: 10.1016/j.jhip.2024.11.004

Zepeng Zhang , Ju Liu , Yi Wang , Xiwen Li , Manman Guo , Menglei Ding , Tongtong Zhu , Lei Zhang

Objective

Yiwei Decoction (YWD) is an ancient TCM formula with historical use in treating chronic atrophic gastritis (CAG). However, its pharmacodynamic mechanisms remain poorly understood. This study aims to study the effect of YWD on CAG through network pharmacology and experimental verification.

Methods

UPLC/MS and the SwissADME database were employed to identify active compounds in YWD. YWD targets were screened by SwissTargetPrediction databases, CAG targets were screened by databases, and the two were intersected for PPI network analysis. The target prediction was performed by GO and KEGG analysis. H₂O₂-induced injury models were established in zebrafish and GES-1 cells, which were subsequently treated with varying doses of YWD. Oxidative stress indicators and apoptosis and inflammation levels in zebrafish and GES-1 cells were assessed using fluorescence microscopy, flow cytometry, and microplate reader assays. The binding capabilities of the core components and core targets were examined using molecular docking. Q-PCR and Western blot were employed to analyze the expression levels of Nrf2, Keap1, and HO-1, respectively.

Results

Forty-nine compounds were identified from YWD. Network pharmacological analysis suggested that YWD may treat CAG by modulating redox-related signaling pathways, inhibiting apoptosis, and reducing inflammation. Subsequent in vitro and in vivo experiments validated these predictions. YWD effectively mitigated H₂O₂-induced oxidative stress in zebrafish and GES-1 cells, suppressing ROS and decreasing apoptosis. YWD reduced inflammation in gastric epithelial cells. Molecular docking results suggested that methylophiopogonanone A and imperatorin may play a key role in the treatment of YWD. Mechanistically, YWD activated the Nrf2 signaling pathway, downregulated Keap1 expression, and upregulated HO-1 and Bcl2 expression.

Conclusion

YWD could improve oxidative stress indicators, inhibiting cell apoptosis, reducing inflammation, and its molecular mechanism of the CAG treatment may be through the Keap1/Nrf2/HO-1 pathways, and to promote the body's antioxidant system.

目的益胃汤是治疗慢性萎缩性胃炎（CAG）的古方。然而，其药效学机制仍然知之甚少。本研究旨在通过网络药理学和实验验证的方法，研究YWD对CAG的影响。方法采用suplc /MS和SwissADME数据库对黄芩中有效成分进行鉴定。YWD靶点通过SwissTargetPrediction数据库筛选，CAG靶点通过数据库筛选，并将两者相交进行PPI网络分析。采用GO和KEGG分析进行靶区预测。在斑马鱼和GES-1细胞中建立h2o2诱导的损伤模型，随后用不同剂量的YWD处理。利用荧光显微镜、流式细胞术和微孔板阅读器检测斑马鱼和GES-1细胞的氧化应激指标、凋亡和炎症水平。利用分子对接技术检测核心组分与核心靶点的结合能力。采用Q-PCR和Western blot分别分析Nrf2、Keap1和HO-1的表达水平。结果从黄芪中鉴定出49个化合物。网络药理学分析表明，YWD可能通过调节氧化还原相关信号通路、抑制细胞凋亡、减轻炎症来治疗CAG。随后的体外和体内实验验证了这些预测。YWD可有效减轻h2o2诱导的斑马鱼和GES-1细胞氧化应激，抑制ROS，减少细胞凋亡。YWD减轻了胃上皮细胞的炎症。分子对接结果提示，甲基参黄酮A和欧前胡素可能在治疗青光眼中起关键作用。机制上，YWD激活Nrf2信号通路，下调Keap1表达，上调HO-1和Bcl2表达。结论ywd能改善氧化应激指标，抑制细胞凋亡，减轻炎症，其治疗CAG的分子机制可能是通过Keap1/Nrf2/HO-1通路，促进机体抗氧化系统。

{"title":"Network pharmacology-based study on the mechanism of Yiwei Decoction in chronic atrophic gastritis and experimental assessment","authors":"Zepeng Zhang , Ju Liu , Yi Wang , Xiwen Li , Manman Guo , Menglei Ding , Tongtong Zhu , Lei Zhang","doi":"10.1016/j.jhip.2024.11.004","DOIUrl":"10.1016/j.jhip.2024.11.004","url":null,"abstract":"<div><h3>Objective</h3><div>Yiwei Decoction (YWD) is an ancient TCM formula with historical use in treating chronic atrophic gastritis (CAG). However, its pharmacodynamic mechanisms remain poorly understood. This study aims to study the effect of YWD on CAG through network pharmacology and experimental verification.</div></div><div><h3>Methods</h3><div>UPLC/MS and the SwissADME database were employed to identify active compounds in YWD. YWD targets were screened by SwissTargetPrediction databases, CAG targets were screened by databases, and the two were intersected for PPI network analysis. The target prediction was performed by GO and KEGG analysis. H<sub>2</sub>O<sub>2</sub>-induced injury models were established in zebrafish and GES-1 cells, which were subsequently treated with varying doses of YWD. Oxidative stress indicators and apoptosis and inflammation levels in zebrafish and GES-1 cells were assessed using fluorescence microscopy, flow cytometry, and microplate reader assays. The binding capabilities of the core components and core targets were examined using molecular docking. Q-PCR and Western blot were employed to analyze the expression levels of Nrf2, Keap1, and HO-1, respectively.</div></div><div><h3>Results</h3><div>Forty-nine compounds were identified from YWD. Network pharmacological analysis suggested that YWD may treat CAG by modulating redox-related signaling pathways, inhibiting apoptosis, and reducing inflammation. Subsequent <em>in vitro</em> and <em>in vivo</em> experiments validated these predictions. YWD effectively mitigated H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in zebrafish and GES-1 cells, suppressing ROS and decreasing apoptosis. YWD reduced inflammation in gastric epithelial cells. Molecular docking results suggested that methylophiopogonanone A and imperatorin may play a key role in the treatment of YWD. Mechanistically, YWD activated the Nrf2 signaling pathway, downregulated Keap1 expression, and upregulated HO-1 and Bcl2 expression.</div></div><div><h3>Conclusion</h3><div>YWD could improve oxidative stress indicators, inhibiting cell apoptosis, reducing inflammation, and its molecular mechanism of the CAG treatment may be through the Keap1/Nrf2/HO-1 pathways, and to promote the body's antioxidant system.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 277-290"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary metabolites from the cold-seep-derived fungus Penicillium sp. SCSIO 41425 and their free radical scavenging activity 冷藏青霉 SCSIO 41425 的次生代谢物及其自由基清除活性

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-11-05 DOI: 10.1016/j.jhip.2024.10.002

Yi Chen , Ying Liu , Jianglian She , Mengjing Cong , Junfeng Wang , Lalith Jayasinghe , Yonghong Liu , Xuefeng Zhou

Objective

To study the chemical compositions from Penicillium sp. SCSIO 41425 and explore their DPPH radical scavenging activity.

Methods

Ethyl acetate extract of Penicillium sp. SCSIO 41425 was separated and purified by silica gel, Ostade-cylsilane (ODS), semi-preparative HPLC, and thin layer chromatography, and their structures were determined by spectroscopic analysis and comparison with the reported literatures.

Results

A total of 18 compounds were isolated from Penicillium sp. SCSIO 41425, including one new compound, (2′R,3′R)-4-(3-hydroxybutan-2-yl)-3,6-dimethylbenzene-1,2-diol (1) and seventeen known compounds (2–18). Their structures were elucidated by detailed NMR and ECD calculations. Compounds 4 and 5 exhibited potent DPPH radical scavenging activity, with EC₅₀ values of 8.42 and 6.62 μg/mL, which were stronger than the positive control ascorbic acid (EC₅₀, 11.22 μg/mL).

Conclusion

This study expands the natural product library of marine cold-seep-derived fungus and provides marine-derived drug source molecules for potent antioxidants.

方法用硅胶、Ostade-cylsilane (ODS)、半制备高效液相色谱和薄层色谱分离纯化青霉SCSIO 41425的乙酸乙酯提取物，通过光谱分析并与文献报道比较确定其结构。结果从青霉菌 SCSIO 41425 中分离出 18 个化合物，包括一个新化合物 (2′R,3′R)-4-(3-hydroxybutan-2-yl)-3,6-dimethylbenzene-1,2-diol (1) 和 17 个已知化合物 (2-18)。通过详细的 NMR 和 ECD 计算阐明了它们的结构。化合物 4 和 5 具有很强的 DPPH 自由基清除活性，EC50 值分别为 8.42 和 6.62 μg/mL，强于阳性对照抗坏血酸（EC50，11.22 μg/mL）。

{"title":"Secondary metabolites from the cold-seep-derived fungus Penicillium sp. SCSIO 41425 and their free radical scavenging activity","authors":"Yi Chen , Ying Liu , Jianglian She , Mengjing Cong , Junfeng Wang , Lalith Jayasinghe , Yonghong Liu , Xuefeng Zhou","doi":"10.1016/j.jhip.2024.10.002","DOIUrl":"10.1016/j.jhip.2024.10.002","url":null,"abstract":"<div><h3>Objective</h3><div>To study the chemical compositions from <em>Penicillium</em> sp. SCSIO 41425 and explore their DPPH radical scavenging activity.</div></div><div><h3>Methods</h3><div>Ethyl acetate extract of <em>Penicillium</em> sp. SCSIO 41425 was separated and purified by silica gel, Ostade-cylsilane (ODS), semi-preparative HPLC, and thin layer chromatography, and their structures were determined by spectroscopic analysis and comparison with the reported literatures.</div></div><div><h3>Results</h3><div>A total of 18 compounds were isolated from <em>Penicillium</em> sp. SCSIO 41425, including one new compound, (2′<em>R</em>,3′<em>R</em>)-4-(3-hydroxybutan-2-yl)-3,6-dimethylbenzene-1,2-diol (<strong>1</strong>) and seventeen known compounds (<strong>2</strong>–<strong>18</strong>). Their structures were elucidated by detailed NMR and ECD calculations. Compounds <strong>4</strong> and <strong>5</strong> exhibited potent DPPH radical scavenging activity, with EC<sub>50</sub> values of 8.42 and 6.62 μg/mL, which were stronger than the positive control ascorbic acid (EC<sub>50</sub>, 11.22 μg/mL).</div></div><div><h3>Conclusion</h3><div>This study expands the natural product library of marine cold-seep-derived fungus and provides marine-derived drug source molecules for potent antioxidants.</div></div>","PeriodicalId":100787,"journal":{"name":"Journal of Holistic Integrative Pharmacy","volume":"5 4","pages":"Pages 257-261"},"PeriodicalIF":0.0,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The versatility of apigenin: Especially as a chemopreventive agent for cancer 芹菜素用途广泛：特别是作为一种癌症化学预防剂

Journal of Holistic Integrative Pharmacy

Pub Date : 2024-11-04 DOI: 10.1016/j.jhip.2024.10.001

Om Prakash , Amit Kumar , Salil Tiwari, Priyanka Bajpai

Apigenin, a naturally occurring flavonoid found in fruits and vegetables, has received substantial attention due to its various pharmacological effects, particularly in cancer therapy. This review delves deeply into apigenin's phytochemical properties and pharmacological activity, with a particular emphasis on its potential as a targeted cancer therapy. We conducted an exhaustive literature study to investigate the molecular processes underlying apigenin's anticancer actions, such as its ability to induce apoptosis, block angiogenesis, and decrease metastasis. We also examine its synergistic effects with conventional chemotherapy drugs and its potential as an adjuvant therapy. Furthermore, the paper discusses current advances in nanoparticle-based delivery systems that improve the bioavailability and efficacy of apigenin in cancer treatment. This detailed investigation aims to provide insights into apigenin's therapeutic capabilities and future possibilities in targeted cancer treatment.

芹菜素是一种存在于水果和蔬菜中的天然类黄酮，由于其各种药理作用，尤其是在癌症治疗方面的作用，芹菜素受到了广泛关注。这篇综述深入探讨了芹菜素的植物化学特性和药理活性，并特别强调了其作为癌症靶向疗法的潜力。我们进行了详尽的文献研究，探讨了芹菜素抗癌作用的分子过程，如诱导细胞凋亡、阻断血管生成和减少转移的能力。我们还研究了芹菜素与传统化疗药物的协同作用及其作为辅助疗法的潜力。此外，本文还讨论了基于纳米颗粒的给药系统在提高芹菜素在癌症治疗中的生物利用度和疗效方面的最新进展。这项详细研究旨在深入探讨芹菜素的治疗能力以及未来在癌症靶向治疗方面的可能性。

引用次数: 0